Announcements Trials
Browse Landscape

Status

Completed 94Terminated 37Recruiting 31Active not recruiting 22Unknown 17Withdrawn 5Suspended 3Not yet recruiting 3No longer available 1Enrolling by invitation 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 4Thoracic 2Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 4Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Metastatic gpNMB Expressing Triple Negative Breast Cancer 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Diseases 1Brain Neoplasms 1Advanced Breast Cancer (Female) 1

Interventions

pegilodecakin 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × Carcinoma, Renal Cell × Breast × Clear all
NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡